STAT News

JANUARY 6, 2023

Food and Drug Administration has granted accelerated approval to the widely anticipated Alzheimer’s drug from Eisai and Biogen, a key question is the extent to which payers — private and public — will cover the treatment. Such decisions are based on myriad factors, starting with the average $26,500 price tag.

Drugs 119

Drugs Clinical Trials Clinical Trials Medicine 119

pharmaphorum

DECEMBER 24, 2021

Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer’s programmes, as the FDA awards a fast-track designation to lecanemab, their follow-up to recently approved Aduhelm. The post Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA appeared first on.

Drugs 110

Drugs FDA Approval Trials Marketing 110

pharmaphorum

MAY 10, 2022

With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer’s disease therapy lecanemab, which is now fully filed with the FDA. Biogen and Eisai have another go appeared first on. Here we go again. The post Exit Aduhelm, enter lecanemab.

FDA Approval 40

FDA Approval Trials Clinical Trials Clinical Trials 40

XTalks

APRIL 18, 2024

Joint makers Biogen and Eisai decided to pull Aduhelm because of the continuing questions and lower-than-expected uptake by insurers and providers due to its high cost. Previously, Roche secured an FDA breakthrough tag for another one of its Alzheimer’s blood tests that detects levels of pTau-181 and ApoE4 (apolipoprotein e4).

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

pharmaphorum

DECEMBER 17, 2021

Biogen and partner Eisai have said they will provide details next March for the confirmatory trial that will be needed to upgrade the drug’s accelerated approval for controversial Alzheimer’s drug Aduhelm to a full one.

Trials 52

Trials Sales Marketing FDA Approval 52

XTalks

JUNE 9, 2021

Biogen developed aducanumab in partnership with Japanese pharmaceutical company Eisai. Aducanumab Controversy and Price Tag. Aducanumab is a human IgG1 monoclonal antibody that binds to aggregated forms of amyloid beta to help reduce its buildup. Evidence for aducanumab’s efficacy has been highly contested.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

pharmaphorum

DECEMBER 7, 2021

That finding could provide some comfort to Biogen and Eisai, whose recently-approved amyloid-targeting drug Aduhelm (aducanumab) is struggling to gain traction in the market on the back of unconvincing efficacy data, safety concerns and a high price tag.

Drugs 52

Drugs Clinical Trials Clinical Trials Scientist 52